KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
scientific article published on 2 November 2009
Matthew T Seymour
Catherine L Daly
Angela M Meade